Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by StrikingMooseon Mar 20, 2018 9:09am

168 Views

Post# 27745087

RE:RE:Level 2 anyone?

This one prettier

Level 2 Quote

Level two quotes - Bid
Number of Shares		Bid Price
611,500 shares	611,500	0.450
8,000 shares	8,000	0.440
5,000 shares	5,000	0.435
64,500 shares	64,500	0.430
1,000 shares	1,000	0.425
133,000 shares	133,000	0.420
100,000 shares	100,000	0.415
27,000 shares	27,000	0.410
5,000 shares	5,000	0.405
185,500 shares	185,500	0.400

Level two quotes - Ask
Ask Price	Number of Shares
0.450	708,500	708,500 shares
0.460	18,500	18,500 shares
0.465	13,500	13,500 shares
0.470	30,000	30,000 shares
0.475	50,000	50,000 shares
0.480	489,000	489,000 shares
0.485	20,000	20,000 shares
0.490	45,000	45,000 shares
0.495	5,000	5,000 shares
0.500	36,000